The use of HT-SPR is critical to innovating new antibodies quickly in discovery and development of therapies and vaccines. This webinar covers:
Presented by Dan Bedigner, PhD, expert in SPR/HT-SPR and modern-day antibody discovery workflows. Dan brings a wealth of knowledge after being at biotech companies such as Xoma, Abgenix, and diaDexus and now leads Carterra’s Applications Science Team.